Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance
Labcorp (LH) reported Q3 2026 revenue of $3.81B, up 6.9% YoY, and adjusted EPS of $4.78, up 14.5%. The company raised full-year guidance, with revenue growth now expected between 5.9% and 6.7%, and adjusted EPS between $18.30 and $18.70. Labcorp also announced several acquisitions and FDA approvals for new diagnostic tests.
How this was made
The 30-second read
Why it matters
The combined earnings beat, guidance lift, and regulatory win provide fresh, material information that can drive the stock higher in the near term.
Market read
The earnings beat and guidance raise are likely to generate buying interest, while the FDA approval adds a catalyst for specialty testing revenue growth.
What to watch
Integration risk of multiple acquisitions and potential regulatory delays for new tests.
Background
Labcorp’s Q3 2026 earnings release includes revenue growth, EPS beat, a raised full‑year outlook, FDA approval of a melanoma companion diagnostic, and several acquisition agreements.
Ticker impact
Labcorp reported Q3 2026 results beating estimates and raised full-year revenue and adjusted EPS guidance.
likely upward pressure as the market prices in higher guidance and the new FDA-approved melanoma test.
Guidance lift and regulatory win are material, fresh information that can move the share price today.
Market effects
Boosts confidence in the healthcare diagnostics and specialty testing sector.
U.S. equity markets, especially health‑care stocks.
Moderate, as Labcorp’s global operations may influence peers worldwide.
Counterpoint
If the guidance raise is already priced in, the stock could face a short‑term pull‑back.
Key entities
- CompanyLabcorp Holdings Inc.
Global laboratory services provider (NYSE: LH).
- PartnerPGDx
Provider of the elio® tissue complete CDx diagnostic approved by the FDA.
